TPX-0005
|
|
TPX-0005 속성
- 밀도
- 1.46±0.1 g/cm3(Predicted)
- 저장 조건
- Store at -20°C
- 용해도
- DMSO:35.0(Max Conc. mg/mL);98.5(Max Conc. mM)
Ethanol:10.0(Max Conc. mg/mL);28.1(Max Conc. mM)
- 물리적 상태
- 결정성 고체
- 산도 계수 (pKa)
- 10.79±0.60(Predicted)
- 색상
- White to off-white
- InChI
- InChI=1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11H,8H2,1-2H3,(H,20,25)(H,22,23)/t10-,11+/m0/s1
- InChIKey
- FIKPXCOQUIZNHB-WDEREUQCSA-N
- SMILES
- O1C2=CC=C(F)C=C2[C@@H](C)NC2C=CN3C(N=2)=C(C=N3)C(=O)NC[C@@H]1C
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
TPX-0005 C화학적 특성, 용도, 생산
개요
Ropotrectinib (TPX-0005; TP Therapeutics, San Diego, CA, USA) is a nextgeneration ROS1 inhibitor, a novel three-dimensional macrocyle with a much smaller size (MW <370) than current ROS1 inhibitors. It was specifically designed to overcome resistance mutations. Preclinical studies have shown activity against gatekeeper and solvent mutations, including G2032R, D2033N, L2026M, S1986F/Y, L1951R, and kinases involved in bypass signaling such as focal adhesion kinase, SRC proto-oncogene, and non-receptor tyrosine kinase [102, 103].개요
Repotrectinib, also known as TPX-0005, is a multikinase (ROS1, ALK, and TRKA/B/C) inhibitor that is tested in an ongoing first-in-human phase 1/2 trail (NCT03093116).Clinical Use
Repotrectinib has advantage with central nervous system (CNS) penetration, aimed to target both wide-type (WT) and solvent-front mutations (SFM) kinases and other resistance mutations including ROS1-G2032R and ROS1-D2033N, TRKA-G595R, TRKB-G639R, TRKC-G623R, and ALK-G1202R.target
Primary targets: NTRK, ROS, ALTTPX-0005 준비 용품 및 원자재
원자재
준비 용품
TPX-0005 공급 업체
글로벌( 159)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Zhengzhou Anhuida Chemical Co., Ltd | +8615903659408 |
admin@ahdchem.com | China | 294 | 58 |
Jinan Million Pharmaceutical Co., Ltd | +86-531-68659554 +8613031714605 |
info@millionpharm.com | China | 191 | 58 |
Hebei Yanxi Chemical Co., Ltd. | +86-17531190177; +8617531190177 |
peter@yan-xi.com | China | 6011 | 58 |
Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21671 | 55 |
Biochempartner | 0086-13720134139 |
candy@biochempartner.com | CHINA | 967 | 58 |
BOC Sciences | +1-631-485-4226 |
inquiry@bocsci.com | United States | 19553 | 58 |
Alchem Pharmtech,Inc. | 8485655694 |
sales@alchempharmtech.com | United States | 63711 | 58 |
Zhengzhou Alfa Chemical Co.,Ltd | +8618530059196 |
sale04@alfachem.cn | China | 13056 | 58 |
HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 |
sales@hzclap.com | CHINA | 6313 | 58 |
Qiuxian Baitai New Material Co., LTD | +8618330912755 |
sale2@hbyalin.com | China | 1677 | 58 |
TPX-0005 관련 검색:
TPX-0131
CSF1R-IN-2
17,19-Metheno-1H,5H-cyclopent[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one, 7-fluoro-2,3,3a,12,13,20a-hexahydro-11-methyl-, (3aS,11R,20aR)-
TPX-0046
Entrectinib
LOXO-195
LOXO-195
NVP-BKM120 (Hydrochloride)
Crizotinib
Lorlatinib (PF-06463922)